Body Mass Index Decrease Has a Distinct Association with Alzheimer's Disease Pathophysiology in APOE ɛ4 Carriers and
1Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.
Journal of Alzheimer'S Disease : JAD
|October 16, 2023
Summary
Tracking body mass index (BMI) changes in older adults is significant. Faster BMI declines correlate with increased Alzheimer
Area of Science:
- Neuroscience
- Genetics
- Gerontology
Background:
- Body mass index (BMI) changes are potentially linked to Alzheimer's disease (AD) pathology.
- The influence of the apolipoprotein E ɛ4 (APOE ɛ4) allele on this association remains unclear.
Purpose of the Study:
- To investigate the relationship between BMI changes and AD pathologies.
- To differentiate these associations based on APOE ɛ4 carrier status.
Main Methods:
- Analysis of 862 non-demented participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least two BMI measurements.
- Examined associations between BMI slopes and longitudinal changes in amyloid-beta (Aβ) accumulation, neurodegeneration, cognition, and tau deposition.
- Stratified analyses by Aβ and APOE ɛ4 status.
Main Results:
- In individuals with amyloid-beta plaques and without the APOE ɛ4 allele, faster BMI declines were associated with increased Aβ accumulation, brain hypometabolism, memory decline, and executive dysfunction.
- Among individuals without amyloid-beta plaques, faster BMI decreases correlated with faster Aβ accumulation in APOE ɛ4 carriers.
- Faster BMI declines were linked to cognitive decline (memory and executive function) in both APOE ɛ4 carriers and non-carriers without amyloid-beta plaques.
Conclusions:
- Body weight fluctuations, particularly declines, are significantly associated with Alzheimer's disease progression.
- The APOE ɛ4 genotype modulates the relationship between BMI changes and AD biomarkers and cognitive decline.
- Monitoring BMI in older adults offers valuable insights into AD risk and progression, especially when considering genetic factors.
More Related Videos
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
Related Concept Videos
Alzheimer's Disease: Overview
503
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503
Alzheimer's Disease: Treatment
211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
